European Patent Office 2017 Inventor Award Goes to Employee of Siemens Healthineers

Siemens HealthineersThe European Patent Office has honored Dutch product manager Jan van den Boogaart, 57, from Siemens Healthineers, and his Austrian research colleague Prof. Oliver Hayden, 45, with the 2017 European Inventor Award for the method they developed together for the automated identification of malaria. Thanks to their patented method, it could be possible to perform malaria tests using the Advia 2120i hematology system as part of a complete blood count in the future.

"The method starts by analyzing volumes of data already in hand," says van den Boogaart. "I firmly believe we can make full use of this potential to identify more by hematological means than we could ever have imagined previously." A malaria infection leaves traces in the blood. To detect those traces, specific parameters are measured as part of a CBC. Van den Boogaart compared blood samples from non-infected blood specimens with malaria-infected specimens from South Africa. Van den Boogaart compiled the data in a big Excel file and also listed the measurement data put out by the Advia 2120i hematology system. He and Hayden, who also worked for Siemens Healthineers for ten years, were then able to identify a combination of parameters that define whether a patient has malaria. From those, they developed the method for the Advia 2120i hematology system.

As is normal with medical products, the development phase will now be followed by comprehensive clinical studies. Even that doesn't mean the end of the research process. "We are currently gathering more samples to investigate whether this method could be applied to other pathogens in principle," adds van den Boogaart. Automated malaria detection offers an insight into what might still be possible. The Inventor Award and the people's choice award are the EPO's way of recognizing committed individuals who drive technological progress forward with their new ideas and dedication. Dr. Torsten Niederdränk, head of the Siemens Healthineers Technology Center, also knows how important this kind of recognition is: "Inventions like these demand a lot of creativity and passion, and of course a lot of work besides. Committed employees who are dedicated to research over and above their regular areas of activity are what drive our innovations forward."

Siemens Healthineers looks back on a 120-year-old history of innovation. Around 7.660 employees, 17 percent of the entire company, work in research and development (R&D). A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products. Last fiscal year, the company invested one billion Euros in R&D and 1,600 new inventions were announced. Globally, the company has over 12,500 granted patents. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers worldwide.

For further information, please visit:
https://www.epo.org/learning-events/european-inventor/finalists.html

About Siemens Healthineers
Siemens Healthineers is the separately managed healthcare business of Siemens AG enabling healthcare providers worldwide to meet their current challenges and to excel in their respective environments. A leader in medical technology, Siemens Healthineers is constantly innovating its portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. Siemens Healthineers is also actively developing its digital health services and enterprise services. To help customers succeed in today's dynamic healthcare marketplace, Siemens Healthineers is championing new business models that maximize opportunity and minimize risk for healthcare providers.

In fiscal 2016, which ended on September 30, 2016, Siemens Healthineers generated revenue of €13.5 billion and profit of over €2.3 billion and has about 46,000 employees worldwide.

Most Popular Now

Philips Launches HealthSuite Clinical Tr…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to...

New AI Diagnostic can Predict COVID-19 w…

Researchers at King's College London, Massachusetts General Hospital and health science company ZOE have developed an artificial intelligence diagnostic that can predict whether someone is likely to have COVID-19 based...

Biomax Provides AI-Based Semantic Search…

The bioinformatics company Biomax, headquartered in Planegg, Germany, makesitssemantic search platform AILANI available free of charge to research institutes around the world in order to support the rapid and successful...

First Virtual DMEA to Open with a Wide R…

16 - 18 June 2020, Berlin, Germany. Under the heading 'DMEA sparks' and taking place for the first time, this year's DMEA is an entirely virtual event. From 16 to 18...

COVID-19 and Health Tech: Building on th…

Highland Marketing's advisory board met to discuss the health tech response to the coronavirus outbreak. In many areas, this has been hugely impressive: but there are gaps, and there will...

InsurTech Hub Munich and dmac/Digital He…

InsurTech Hub Munich (ITHM) and dmac - Medical Valley Digital Health Application Center part of the Digital Health Hub Nuremberg/Erlangen announce a new cross-industry accelerator for the second half of...

Viveo Health Offers Free Telemedicine So…

Viveo Health, a global e-Health innovator, is making its 'Virtual Office for Doctors' platform free of charge to doctors and other medical professionals worldwide in light of the surge in...

The Dedalus Group, Participated by Ardia…

The Dedalus Group, a leading European company, and one of the worldwide main ones, active in clinical healthcare information systems to support clinical professionals and organizations in order to improve...

Supercomputer Simulations Present Potent…

Several drugs approved for treating hepatitis C viral infection were identified as potential candidates against COVID-19, a new disease caused by the SARS-CoV-2 coronavirus. This is the result of research...

The COVID-19 pandemic reveals the potent…

Two new articles provide insights on the use of telehealth or virtual care in the age of COVID-19 and beyond, pointing to its value to not only prevent contagious diseases...

WiFi SPARK Works with Visionable to Conn…

Seven NHS Trusts are using technology developed by WiFi SPARK in response to an urgent request from leading NHS Trusts to find a way to connect hospital patients with their...

Digital Contact Tracing for COVID-19: An…

An article in CMAJ (Canadian Medical Association Journal) analyzes the strengths and limitations of digital contact tracing for people infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to help...